Mycobacterium (M. leprae), involves loss of intraepidermal nerve fibers and pain receptors in clinical skin biopsies (Facer et al., 2000). The absence of inflammatory pain may thus result from effects of mycolactone on both inflammatory cells and cutaneous nociceptors.
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Metazoan organisms employ a distinct type of programmed cell death, called apoptosis, to eliminate severely damaged or infected cells. The Bcl-2 gene family encodes proteins that control apoptotic signaling via the cell-intrinsic, mitochondrial pathway (Cory and Adams, 2002) . Two structural subclasses of this family share Bcl-2 homology (BH) motifs: (1) BH3 proteins (e.g., Bim, Bid, Bad, Bmf, Puma, and Noxa), which harbor a single BH motif and promote apoptosis; and (2) multi-BH proteins, which possess three or four BH regions and act either as apoptosis activators (e.g., Bax and Bak) or inhibitors (e.g., Bcl-2, Bcl-x L , Bcl-w, and Mcl-1). Some BH3 factors promote apoptosis by sequestering prosurvival Bcl-2 proteins from Bax and Bak, whereas others bind directly to Bax or Bak to drive activation. The BH3 motifan 26 amino acid a-helical peptideinteracts with a hydrophobic groove on the cognate binding partner.
Viruses often encode orthologs of cellular antiapoptotic proteins to prevent host cell death and extend viral replication. Epstein-Barr virus (EBV) latently infects human B cells, contributing to cancers such as Burkitt's lymphoma.
EBV encodes a Bcl-2-like decoy, called BHRF1, which blocks host-cell apoptosis (Henderson et al., 1993) . Although small-molecule inhibitors of Bcl-2 proteins are being developed in the clinic (Billard, 2013) , polypeptide inhibitors might have differentiating qualities; however, computational efforts to design biologically active proteins, including Bcl-2 inhibitors, have been limited (Fleishman et al., 2011; Procko et al., 2013) . In this issue of Cell, Procko et al. (2014) employ a computational design method , combined with in-vitro-directed evolution, to generate a potent and selective polypeptide inhibitor of BHRF1 (Procko et al., 2014) .
The computational design procedure developed by Procko et al. (2014) (Figure 1) -dubbed Fold From Loops (FFL)-requires as input the structure of a functional motif and a template scaffold topology that will ''fold'' around this motif and stabilize it. Procko et al. (2014) select the Bim-BH3 helix from the BHRF1:Bim-BH3 cocrystal structure (Kvansakul et al., 2010) as the functional motif and folding nucleus. Structural homologs of the three-helix bundle target scaffold-a domain derived from a bacterial ribosome-recycling factor-are then assembled around the functional motif using a fragmentbased approach. Subsequently, they perform multiple rounds of sequence minimization and design. The template scaffold guides the assembly of the unique sequences through both atompair distance constraints and topology. They then select 1,000 structures possessing the lowest energy from an ensemble of 5,000 FFL-assembled homologs and align them to the Bim-BH3 peptide in the BHRF1:Bim-BH3 complex. The interface residues outside the Bim-BH3 motif in the docked structures are optimized using ROSETTA (Leaver-Fay et al., 2011) , and the designs are filtered for interface quality and monomer stability. Ultimately, the authors test the 74 designs with the lowest number of buried, unsatisfied hydrogenbonding atoms in the unbound monomer in a yeast display system. Of these, two variants bind BHRF1 with apparent K d values of 60 nM. Notably, the best computational predictor of binding activity is the degree of similarity between the conformations predicted ab initio and the designed structure. BHRF1 binders are further optimized for affinity, specificity, and stability via directed evolution by yeast display to yield a stable, high-affinity (K d = 220 pM) variant named BINDI.
Other methods seeking to constrain conformations of functional protein motifs include stabilizing the helical arrangement of BH3 peptides by covalently linking pairs of residues on one face of the a helix (Azzarito et al., 2013) . The de novo design approach presented by Procko et al. (2014) has one important relative advantage: the stabilizing protein scaffold provides favorable interactions with the target in addition to those provided by the functional peptide motif itself. Indeed, the crystal structure of the BHRF1:BINDI complex shows that the incorporated Bim-BH3 motif contributes only 40% of the total BHRF1-interaction surface. Importantly, directed evolution of the designed scaffold improves stability, further enhancing affinity.
The de novo computational design of a protein that binds tightly and selectively to the surface of a target and exerts a specific biologic activity is an important and exciting advance-it improves substantially over previous approaches of transplanting functional binding epitopes into an existing protein scaffold. Upon modification to facilitate intracellular entry, Procko et al. (2014) find that their inhibitor induces apoptosis of EBV-infected cells. Moreover, on further modification to enable systemic delivery, they observe that the inhibitor attenuates tumor growth and extends host survival in a mouse xenograft model of EBV-positive human lymphoma. This represents the successful design of an entirely novel protein inhibitor with a meaningful, on-target biologic activity.
In future studies, it will be interesting to explore whether this strategy can be applied to diverse types of protein interactions with different template scaffolds. A remaining key challenge is the development of clinically viable methods for intracellular or systemic (preferably nonimmunogenic) delivery of designer proteins. Assessing whether the new approach can be employed not only for functional modulation but also for wider tasks, such as payload delivery of chemotherapeutics or other biologically active compounds, will also be important.
